United States · FDA National Drug Code directory

Creosote Combination 9254

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
63083-9254_9efdecb8-b860-4856-917e-c8b2302a817c
Product NDC
63083-9254
Form
LIQUID
Composition / generic term
Creosote Combination
Labeler
Professional Complementary Health Formulas
Marketing category
UNAPPROVED HOMEOPATHIC
Marketing start / end (source format)
19840815
Source listing expiry
20271231

Source-listed ingredients

  • ACONITUM NAPELLUS WHOLE — 4 [hp_X]/29.5mL
  • AMARYLLIS BELLADONNA WHOLE — 4 [hp_X]/29.5mL
  • BRYONIA ALBA ROOT — 4 [hp_X]/29.5mL
  • HYOSCYAMUS NIGER — 4 [hp_X]/29.5mL
  • IPECAC — 4 [hp_X]/29.5mL
  • LOBELIA INFLATA WHOLE — 4 [hp_X]/29.5mL
  • LOBARIA PULMONARIA — 4 [hp_X]/29.5mL
  • PHOSPHORUS — 5 [hp_X]/29.5mL
  • ANTIMONY POTASSIUM TARTRATE — 6 [hp_X]/29.5mL
  • WOOD CREOSOTE — 6 [hp_X]/29.5mL
  • SILICON DIOXIDE — 6 [hp_X]/29.5mL
  • HUMAN SPUTUM, BORDETELLA PERTUSSIS INFECTED — 30 [hp_X]/29.5mL
  • CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED) — 30 [hp_X]/29.5mL

These values do not establish equivalence or a dose recommendation.

Packages

  • 29.5 mL in 1 BOTTLE, DROPPER (63083-9254-1) · 63083-9254-1

Source and coverage

Open FDA National Drug Code directory →

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →